This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Multiple drugs from each category have been proven effective. Marketized drugs have encountered market demands, also boosted personalized medication developments aiming at a broader range of recipients. Still, disease establishment dilemmas and FDA drug approvals give rise to ethical concerns, posing obstacles in the field's development.
== Distribution == Cold seeps were discovered in 1983 by Charles Paull and colleagues on the Florida Escarpment in the Gulf of Mexico at a depth of 3,200 meters (10,500 ft). Since then, seeps have been discovered in many other parts of the world's oceans. Most have been grouped into five biogeographic provinces: Gulf of Mexico, Atlantic, Mediterranean, East Pacific, and West Pacific, but cold seeps are also known from under the ice shelf in Antarctica, the Arctic Ocean, the North Sea, Skagerrak, Kattegat, the Gulf of California, the Red Sea, the Indian Ocean, off southern Australia, and in the inland Caspian Sea. In the Pacific Northwest, a cold seep called Pythia's Oasis was discovered in 2015. With the recent discovery of a methane seep in the Southern Ocean, cold seeps are now known in all major oceans. Cold seeps are common along continental margins in areas of high primary productivity and tectonic activity, where crustal deformation and compaction drive emissions of methane-rich fluid. Cold seeps are patchily distributed, and they occur most frequently near ocean margins from intertidal to hadal depths. In Chile, cold seeps are known from the intertidal zone, in Kattegat, the methane seeps are known as "bubbling reefs" and are typically at depths of 0–30 m (0–100 ft), and off northern California, they can be found as shallow as 35–55 m (115–180 ft). Most cold seeps are located considerably deeper, well beyond the reach of ordinary scuba diving, and the deepest seep community known is found in the Japan Trench at a depth of 7,326 m (24,035 ft).
Nobel physics laureate Steven Weinberg said that the Nobel committee "fleeced" Dyson, but Dyson remarked in 2009, "I think it's almost true without exception if you want to win a Nobel Prize, you should have a long attention span, get hold of some deep and important problem and stay with it for ten years. That wasn't my style." Dyson was a regular contributor to The New York Review of Books, and published a memoir, Maker of Patterns: An Autobiography Through Letters in 2018. In 2012 Dyson published (with William H. Press) a fundamental new result about the prisoner's dilemma in the Proceedings of the National Academy of Sciences of the United States of America.
Insulin icodec, sold under the brand name Awiqli, is an ultralong-acting basal insulin analogue used in the treatment of diabetes. It is administered by subcutaneous injection once weekly. It was developed by Novo Nordisk. Insulin icodec was designed to provide basal insulin coverage with once-weekly dosing. It is approved for medical use in Canada, the European Union, Australia, and in the United States.
=== Dendritogenesis === Local interaction of BDNF with the TrkB receptor on a single dendritic segment is able to stimulate an increase in PSD-95 trafficking to other separate dendrites as well as to the synapses of locally stimulated neurons. PSD-95 localizes the actin-remodeling GTPases, Rac and Rho, to synapses through the binding of its PDZ domain to kalirin, increasing the number and size of spines. Thus, BDNF-induced trafficking of PSD-95 to dendrites stimulates actin remodeling and causes dendritic growth in response to BDNF.
Sources: en.wikipedia.org
According to anonymous sources reported by CNN, Bradley said the struck vessel was going to meet another boat which was bound for Suriname. Five people familiar with Bradley's briefing, including one lawmaker who viewed video of the incident, believed the survivors were signaling for help, rescue, or surrender at the time they were killed. In the classified briefing, Bradley admitted that people killed in the boat may have been the victims of human trafficking. In 1 December press conference the White House reiterated "the president has made it quite clear that if narcoterrorists are trafficking illegal drugs towards the United States, he has the authority to kill them". Karoline Leavitt, press secretary for the Trump administration, stated that "... Secretary Hegseth authorized Admiral Bradley to conduct these kinetic strikes. Admiral Bradley worked well within his authority and the law, directing the engagement to ensure the boat was destroyed and the threat to the United States of America was eliminated." According to The Guardian, the administration "argu[es] that its objective was to ensure the complete destruction of the boat". Bradley was promoted after the strike. The Washington Post also reported that intelligence analysts observing the boat via surveillance aircraft were increasingly confident that it was carrying drugs, and that "protocols were changed after the strike", providing for rescue of survivors, according to anonymous sources.
== Reactions == The imidazole groups on TCDI can be easily displaced, allowing it to act as a safer alternative to thiophosgene. This behaviour has been used in the Corey–Winter olefin synthesis. It may also replace thioacyl chlorides (RC(S)Cl) in the Barton–McCombie deoxygenation. Other uses include the synthesis of thioamides and thiocarbamates. Like the analogous CDI, it may be used for peptide coupling.
== Early life == Gemma Clair Collins was born on 31 January 1981 at Oldchurch Hospital in Romford, East London. She is the daughter of Joan Collins (née Williams; 21 February 1955 — 29 July 2026), who worked as a part-time hairdresser, and Alan Collins, the director of Unisystems Freight, an import-export shipping company. She has an older brother named Russell, who is also a director of their father's company. Shortly after her birth, the family moved from a house in Collier Row and Collins was raised in Rise Park where she attended Rise Park Infant School. Collins described her childhood as being "filled with love" and said that although money was "tight", her father still managed to take them on family holidays and said she has "very happy memories" of her early years. Collins then went on to attend Frances Bardsley Academy for Girls. She enjoyed performing arts from a young age and attended dance lessons and stage school. At the age of 14, she began attending the Sylvia Young Theatre School and successfully auditioned for a part in The Sound of Music. Collins' mother was encouraging and said she knew that her daughter would one day become famous. Collins was bullied at school for being outgoing and confident, and so following the success of her father's business, her parents decided to move her to Raphael Independent School, a private school, for her final year of education. She left school at the age of 16 with a G in GCSE Maths.
The hybrid layer is hydrophobic, acid resistant and tough. The quality of hybrid layer formed decides the strength of resin dentin interface. When the hybrid layer becomes thicker and more uniform, the bond strength is better.
Sources: en.wikipedia.org
Dexlansoprazole was launched as a follow up of lansoprazole in 2009. Dexlansoprazole is an (R)-(+)-enantiomer of lansoprazole, marketed as Dexilant. After oral appliance of the racemic lansoprazole, the circulating drug is 80% dexlansoprazole. Moreover, both enantiomers have similar effects on the proton pump. Consequently, the main advantage of Dexilant is not the fact that it is an enantiopure substance. The advantage is the pharmaceutical formulation of the drug, which is based on a dual release technology, with the first quick release producing a blood plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later.
== Sources == Watkins, Elizabeth Siegel (2009). "From History of Pharmacy to Pharmaceutical History". Pharmacy in History. 51 (1): 3–13. PMID 20027914. (in Japanese) Asai, T. (1985). Nyokan Tūkai. Tokyo: Kōdan-Sha. (in French) Titsingh, Isaac, ed. (1834). [Siyun-sai Rin-siyo/Hayashi Gahō, 1652], Nipon o daï itsi ran; ou, Annales des empereurs du Japon. Paris: Oriental Translation Fund of Great Britain and Ireland....Click link for digitized, full-text copy of this book (in French) Pharmacy Consulting Services | McKesson Archived 14 December 2019 at the Wayback Machine – A landmark study in hospital pharmacy performance based on an extensive literature review and the collective experience of the Health Systems Pharmacy Executive Alliance.
The effectiveness of light therapy for treating seasonal affective disorder (SAD) may be linked to reduced sunlight exposure in the winter months. Light resets the body's internal clock. Studies show that light therapy helps reduce the debilitating depressive symptoms of SAD, such as excessive sleepiness and fatigue, with results lasting for at least 1 month. Light therapy is preferred over antidepressants in the treatment of SAD because it is a relatively safe and easy therapy with minimal side effects. Two methods of light therapy, bright light and dawn simulation, have similar success rates in the treatment of SAD. It is possible that response to light therapy for SAD could be season dependent. Morning therapy has provided the best results because light in the early morning aids in regulating the circadian rhythm. People affected by SAD often have low energy, tend to eat more carbohydrates and sleep longer, but symptoms can vary between people. A Cochrane review conducted in 2019 states the evidence that light therapy's effectiveness as a treatment for the prevention of seasonal affective disorder is limited, although the risk of adverse effects are minimal. Therefore, the decision to use light therapy should be based on a person's preference of treatment.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.